NCT04339036View on ClinicalTrials.gov

CapTemY90 for Grade 2/3 NET Liver Metastases

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

October 7, 2021

Primary Completion Date

May 1, 2026

Study Completion Date

May 1, 2026

Conditions
Neuroendocrine Tumor Grade 2Neuroendocrine Tumors
Interventions
DRUG

Capecitabine Oral Product

Capecitabine 750 mg/m2 twice daily orally for 14 days

DRUG

Temozolomide Oral Product

temozolomide 200 mg/m2 orally on Days 10-14, with 14 days between cycles

COMBINATION_PRODUCT

transarterial radioembolization

Trans-arterial radioembolization (TARE) on Day 7 of cycle 2 and, if needed for the other lobe, Day 7 of either cycle 3 or 4.

Trial Locations (4)

14203

RECRUITING

Roswell Park Comprehensive Cancer Center, Buffalo

19103

RECRUITING

University of Pennsylvania, Philadelphia

33136

RECRUITING

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami

92037

RECRUITING

UC San Diego, La Jolla

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER